<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819870</url>
  </required_header>
  <id_info>
    <org_study_id>125HPS12006</org_study_id>
    <nct_id>NCT01819870</nct_id>
  </id_info>
  <brief_title>Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetic characteristics and safety of
      dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy male subjects are administrated multiple-dose over the period I and II (Crossover) of
      dilatrend SR capsule 32mg and dilatrend tablet 25mg.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCtau</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>AUCtau: Area under the plasma concentration-time curve for each dosing interval (from time 0 to 48 hours sample) determined using the linear trapezoidal rule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg AUCinf</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>AUCinf: Area Under the Concentration time curve with the last concentration extrapolated based on the elimination rate constant Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,max</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>Css,max : Maximum drug concentration in plasma determined directly from individual concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Css,min</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>Css,min : Minimum drug concentration in plasma determined directly from individual concentration-time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg Tss,max</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>Tss,max : Time to reach maximum drug concentration in plasma calculated from [plasma] versus time profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Dilatrend SR Capsule 32mg and Dilatrend tablet 25mg t½</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48hr post‐dose (on last day of each period)</time_frame>
    <description>t½ : Observed terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From 1day to 37 days</time_frame>
    <description>Evaluated safety parameters included: physical examination, vital sign, laboratory test, ECG
adverse event monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Chronic Stable Angina</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Dilatrend SR capsule 32mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilatrend IR tablet 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilatrend SR capsule 32mg</intervention_name>
    <description>1 capsule, oral, once daily, 7days
over the period I&amp;II(crossover)</description>
    <arm_group_label>Dilatrend SR capsule 32mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dilatrend IR tablet 25mg</intervention_name>
    <description>1 tablet, oral, once daily, 7days
over the period I&amp;II(crossover)</description>
    <arm_group_label>Dilatrend IR tablet 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 20 aged and 35aged in healthy male

          -  Body Weight more than 50kg, and within 20% of ideal body weight(IBW).

               -  IBW(kg) = {height(cm)-100}*0.9

          -  Have not any congenital or chronic disease and medical symptoms.

          -  Suitable results of inspections(laboratory test, ECG, etc) within 21 days before IP
             administration.

          -  Agreement with written informed consent

        Exclusion Criteria:

          -  Subject has hypersensitivity reaction or clinically significant history about
             carvedilol or investigator drug.

          -  Clinically significant cardiovascular system, respiratory system, liver, kidney,
             endocrine system, gastrointestinal system, central nervous system, blood tumor, mental
             disease, skin disease, otorhinolaryngologic diseases and so on.

          -  Hypotension(SBP &lt; 105mmHg or DBP &lt; 65mmHg), Hypertension(SBP &gt; 150mmHg or DBP &gt;
             100mmHg)

          -  Heart rate &lt; 50times/minute

          -  Active liver disease or AST, ALT &gt; 1.5*upper limit of normal range

          -  Creatinine clearance &lt; 80mL/min

          -  Subject has a disease affecting drug's ADME or gastrointestinal surgery.

          -  Subject with symptoms of injured or acute disease within 28days before the first IP
             administration.

          -  Subject has a history of drug abuse or a positive reaction for drug abuse at the
             screening test for urine.

          -  Taking ETC medicine including oriental medicine within 14days before the first IP
             administration or Taking OTC medicine within 7days

          -  Subject takes an abnormal meal which affect the ADME of drug.

          -  Previously participate in other trial within 90days.

          -  Previously make whole blood donation within 60days or component blood donation within
             30days before the first IP administration.

          -  Continued to be taking caffeine(caffeine &gt; 5cup/day), drinking(alcohol &gt; 21unit/week,
             1unit = 10g = 12.5mL of pure alcohol) or during clinical trials can not be drunk or
             severe heavy smoker(cigarette &gt; 10cigarettes/day).

          -  Subject with positive reaction about serum test(HBsAg, HCV Ab, HIV Ag/Ab, VDRL)

          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,
             glucose-galactose malabsorption.

          -  An impossible one who participates in clinical trial by investigator's decision
             including for reason of laboratory test result.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital Clinical Trial Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Ran Yoon</last_name>
    <phone>053-420-4950</phone>
    <email>yry@knu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital Clinical Trial Center</name>
      <address>
        <city>Daegu</city>
        <state>eok-dong 2(i)-ga Jung-gu</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>March 29, 2013</last_update_submitted>
  <last_update_submitted_qc>March 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carvedilol</keyword>
  <keyword>Dilatrend SR capsule</keyword>
  <keyword>Dilatrend Tablet</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy male subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

